| Literature DB >> 27145883 |
Stéphane Cullati1, Delphine S Courvoisier2, Angèle Gayet-Ageron2, Guy Haller2,3, Olivier Irion4, Thomas Agoritsas2,5, Sandrine Rudaz2, Thomas V Perneger2.
Abstract
BACKGROUND: Many medical research projects encounter difficulties. The objective of this study was to assess the self-reported frequency of difficulties encountered by medical researchers while conducting research and to identify factors associated with their occurrence.Entities:
Keywords: Barriers; Clinical research; Difficulties; Medical researchers; Research protocols; Switzerland
Mesh:
Year: 2016 PMID: 27145883 PMCID: PMC4855713 DOI: 10.1186/s12874-016-0151-1
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Fig. 1Self-reported difficulties* (rated as medium or great or very great) in clinical research among principal investigators (N = 386)
Characteristics of the 391 completed studies with follow-up questionnaire returned
|
| |
|---|---|
| Study design | |
| Interventional | 180 (46.0) |
| Observational | 211 (54.0) |
| First decision of the research ethics committee ( | |
| Positive, positive with recommendations, or positive with written modifications required | 309 (79.2) |
| Positive with conditions and reassessment, or negative and non-considered, but approved at a later stage | 81 (20.8) |
| Financial sponsorship of the study protocol ( | |
| Public (hospital, university) | 294 (78.0) |
| Private (industry, foundation) | 75 (19.9) |
| Both | 8 (2.1) |
| Link with the industry ( | |
| None | 267 (70.6) |
| Industry with indication of support (funding, drugs, human resources) | 103 (27.2) |
| Industry without indication of support | 8 (2.1) |
| Sample size ( | |
| ≤ 100 | 220 (56.4) |
| > 100 | 170 (43.6) |
| Sample size calculation (N = 384) | |
| Yes | 169 (44.0) |
| No | 215 (56.0) |
| Number of centers | |
| Single | 232 (59.3) |
| Multicenter | 159 (40.7) |
| Research topic | |
| Health or illness (organs, tissues, cells, receptors, etc.) | 91 (23.3) |
| Intervention or treatment | 172 (44.0) |
| Diagnostics method | 25 (6.4) |
| Prognosis | 12 (3.1) |
| Public health, health economics, medical ethic, attitudes | 43 (11.0) |
| Research methods (questionnaires, indicators, measures, etc.) | 41 (10.5) |
| Other, unspecified topic (registries, medical record databases) | 7 (1.8) |
| Clinical specialty | |
| General | 60 (15.3) |
| Psychiatry | 40 (10.2) |
| Cardiology | 35 (9.0) |
| Oncology | 30 (7.7) |
| Infectious diseases | 27 (6.9) |
| Neurology | 16 (4.1) |
| Rheumatology | 7 (1.8) |
| Other clinical specialties | 149 (38.1) |
| Two or more specialties | 27 (6.9) |
| Presence of a statistician in the study team ( | |
| Yes | 98 (25.5) |
| No | 286 (74.5) |
| PI’s training in quantitative methods | |
| None | 164 (41.9) |
| Courses and/or continuing education at the University level | 183 (46.8) |
| Bachelor, master or PhD in quantitative methods | 8 (2.0) |
| Bachelor, master, or PhD in quantitative methods, and courses/continuing education | 36 (9.2) |
| Study published | |
| Yes | 269 (68.8) |
| No | 122 (31.2) |
Univariable associations (one-way ANOVA) with mean number of difficulties in clinical research
| All difficulties (15 items) | Scientifica difficulties (7 items) | Logisticalb difficulties (7 items) | ||||
|---|---|---|---|---|---|---|
| Mean |
| Mean |
| Mean |
| |
| Study design | .45 | .002 | .047 | |||
| Interventional | 2.7 | 0.9 | 1.8 | |||
| Observational | 2.9 | 1.4 | 1.4 | |||
| First decision of the REC | .25 | .89 | .022 | |||
| Positive, positive with recommendations, positive with written modifications required | 2.7 | 1.1 | 1.5 | |||
| Positive with conditions and reassessment, negative/non-consideration | 3.1 | 1.1 | 2.0 | |||
| Origin of the study protocol | <.001 | <.001 | .12 | |||
| Public (hospital, University, etc.) | 3.1 | 1.4 | 1.6 | |||
| Private (industry, foundation) | 1.6 | 0.2 | 1.3 | |||
| Sample size | .33 | .092 | .96 | |||
| ≤ median (100) | 2.9 | 1.3 | 1.6 | |||
| > median | 2.6 | 1.0 | 1.6 | |||
| Number of centers | <.001 | <.001 | .21 | |||
| Single | 3.2 | 1.5 | 1.7 | |||
| Multicenter | 2.1 | 0.6 | 1.5 | |||
| Type of research | .79 | .084 | .006 | |||
| Clinical (intervention, diagnosis, prognosis) | 2.8 | 1.0 | 1.8 | |||
| Others (health/illness, public health/health economics, methods, other) | 2.7 | 1.3 | 1.3 | |||
| Self-reported trainings in quantitative methods | .37 | .16 | .80 | |||
| None | 2.9 | 1.3 | 1.6 | |||
| Any | 2.7 | 1.0 | 1.6 | |||
| Presence of a statistician on study team ( | .086 | <.001 | .54 | |||
| No | 2.9 | 1.3 | 1.6 | |||
| Yes | 2.4 | 0.6 | 1.7 | |||
| Study published | .71 | .90 | .34 | |||
| No | 2.7 | 1.1 | 1.5 | |||
| Yes | 2.8 | 1.1 | 1.6 | |||
aSum of difficulties reported on the following items: literature review, research question, design, data management, data analysis, manuscript writing, and publication in a peer-reviewed journal
bSum of difficulties reported on the following items: approval by the Research Ethic Committee, getting funding, approval by the safety agencies, patient enrollment, data collection, collaboration with caregivers for patient enrollment, recruiting competent staff to conduct the study
Multivariable linear regression of sum of difficulties in clinical research
| All difficulties (15 items) | Scientific difficulties (7 items) | Logistical difficulties (7 items) | ||||
|---|---|---|---|---|---|---|
| Study characteristics: | Difference | 95 % CI | Difference | 95 % CI | Difference | 95 % CI |
| Public sponsorshipa (vs. private) | 1.3 | 0.4,2.1 | 0.9 | 0.4,1.3 | 0.4 | -0.1,0.9 |
| Single center study (vs. multicenter) | 0.8 | 0.1,1.5 | 0.6 | 0.2,1.0 | 0.3 | -0.1,0.7 |
| “Clinical” studyb (vs. otherc) | 0.7 | 0.0,1.3 | 0.1 | -0.2,0.5 | 0.6 | 0.3,1.0 |
Difference = beta coefficients; CI = confidence interval
aPublic hospital, University
b Intervention or diagnosis or prognosis studies
chealth/illness, public health/health economics, methods, other
Difficulties in clinical research by study characteristicsa
| Study characteristics | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Privatebsponsorship | Public sponsorship | Multi center | Single center | Otherc | Clinicald | ||||
| Difficulties with: | % | % |
| % | % |
| % | % |
|
| Literature review (get relevant articles, read, synthesize) | 2.4 | 6.9 | 0.19 | 3.1 | 7.9 | 0.078 | 7.2 | 4.9 | 0.39 |
| Research question (formulation of a main research question and/or hypothesis) | 1.2 | 13.1 | 0.001 | 3.2 | 15.0 | <0.001 | 15.1 | 5.9 | 0.004 |
| Study design (identification of the study design, variables, instruments, analysis, including calculation of the sample size) | 2.4 | 25.8 | <0.001 | 8.2 | 29.1 | <0.001 | 23.3 | 18.0 | 0.21 |
| Approval by the Research Ethics Committee | 12.2 | 17.9 | 0.25 | 11.9 | 20.3 | 0.038 | 12.8 | 20.4 | 0.056 |
| Getting funding | 3.7 | 23.9 | <0.001 | 13.8 | 23.1 | 0.026 | 19.0 | 19.5 | 1.00 |
| Approval by the safety agencies (Swiss Agency for Therapeutic Products, etc.) | 17.3 | 8.3 | 0.023 | 14.6 | 7.0 | 0.024 | 3.9 | 15.7 | <0.001 |
| Patients enrollment | 51.3 | 41.5 | 0.13 | 48.1 | 42.5 | 0.30 | 37.1 | 51.5 | 0.005 |
| Data collection | 19.5 | 28.9 | 0.12 | 22.0 | 30.0 | 0.10 | 26.1 | 27.2 | 0.82 |
| Collaboration with caregivers for patient enrollment | 18.3 | 22.1 | 0.54 | 20.1 | 21.8 | 0.80 | 19.4 | 22.5 | 0.53 |
| Recruitment of competent persons to conduct the study | 12.2 | 22.0 | 0.059 | 16.4 | 22.9 | 0.12 | 16.7 | 23.3 | 0.13 |
| Data management | 6.1 | 20.4 | 0.002 | 10.1 | 21.8 | 0.002 | 19.6 | 14.6 | 0.22 |
| Data analysis (statistical or other) and results interpretation | 3.7 | 26.7 | <0.001 | 10.8 | 29.3 | <0.001 | 23.5 | 20.1 | 0.46 |
| Writing a manuscript for a scientific publication | 1.2 | 23.8 | <0.001 | 8.9 | 25.6 | <0.001 | 20.9 | 16.7 | 0.36 |
| Publication in a peer-reviewed journal | 4.9 | 25.5 | <0.001 | 14.6 | 24.8 | 0.020 | 21.1 | 20.0 | 0.80 |
| Other(s) difficulty(ies) | 3.7 | 5.8 | 0.58 | 5.0 | 5.3 | 1.00 | 8.9 | 1.9 | 0.002 |
aSelected from the multivariable model (Table 3). P-values come from the Fisher’s exact test
bIndustry or foundation
cHealth/illness, public health, methodology, etc
dIntervention or diagnosis or prognosis